A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.
Sponsor: Takeda
Terminated
AG-1749 superior to Gefarnate in ulcer prevention
Listed as NCT00762359, this PHASE3 trial focuses on Duodenal Ulcer and Stomach Ulcer and remains terminated or withdrawn. Sponsored by Takeda, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Asahikawa-shi, Japan , Beppu-shi, Japan , Chiyoda-ku, Japan , Chuuo-ku, Japan , Ebino-shi, Japan , Fujioka-shi, Japan , Fujisawa-shi, Japan , Fukui-shi, Japan , Fukuoka, Japan , Gifu, Japan and 55 more locations